Aerie Pharmaceuticals announced positive 12-month interim safety results for Rhopressa, a once-daily eye drop for patients with glaucoma or ocular hypertension.
Powered by Steuernachrichten
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Once-daily glaucoma drop shows promise
- Details